Tag - ALLO

Developments

FDA grants three FTDs for Allogene’s ALLO-329

Allogene Therapeutics (NASDAQ:ALLO) announced that the FDA has granted three fast track designations (FTDs) for its ALLO-329, a next-generation dual-target CD19/CD70 allogeneic CAR T for the treatment of lupus...

April 8, 2025

Developments

FDA grants RMAT designation to Allogene’s ALLO-316 for patients with RCC

Allogene Therapeutics (NASDAQ:ALLO) has announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to its ALLO-316 for treating adult patients with CD70-positive advanced or metastatic...

October 29, 2024

Tag - ALLO

FDA grants three FTDs for Allogene’s ALLO-329

FDA grants RMAT designation to Allogene’s ALLO-316 for patients with RCC

Subscribe